tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
AORT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsAORT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
Artivion: Positive Clinical Data and Pipeline Progress Support Sustained Growth and Buy Rating
Premium
Ratings
Artivion: Positive Clinical Data and Pipeline Progress Support Sustained Growth and Buy Rating
2M ago
Artivion announces presentations of clinical data from Nexus and AMD trials
Premium
The Fly
Artivion announces presentations of clinical data from Nexus and AMD trials
2M ago
Artivion price target raised to $50 from $40 at Oppenheimer
PremiumThe FlyArtivion price target raised to $50 from $40 at Oppenheimer
5M ago
Artivion price target raised to $40 from $38 at Ladenburg
Premium
The Fly
Artivion price target raised to $40 from $38 at Ladenburg
5M ago
Artivion price target raised to $51 from $50 at Canaccord
Premium
The Fly
Artivion price target raised to $51 from $50 at Canaccord
5M ago
Artivion raises FY25 revenue view to $439M-$445M from $435M-$443M
PremiumThe FlyArtivion raises FY25 revenue view to $439M-$445M from $435M-$443M
5M ago
Artivion announces treatment of first patient in ARTIZEN pivotal trial
Premium
The Fly
Artivion announces treatment of first patient in ARTIZEN pivotal trial
5M ago
AORT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
AORT Upcoming Earnings Report: What to Expect?
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100